Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 60.85
- Piotroski Score 2.00
- Grade Sector Perform
- Symbol (MORF)
- Company Morphic Holding, Inc.
- Price $56.99
- Changes Percentage (0.04%)
- Change $0.02
- Day Low $56.97
- Day High $57.00
- Year High $57.00
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $57.00
- High Stock Price Target $57.00
- Low Stock Price Target $57.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.60
- Trailing P/E Ratio -8.55
- Forward P/E Ratio -8.55
- P/E Growth -8.55
- Net Income $-152,095,000
Income Statement
Quarterly
Annual
Latest News of MORF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Starve Acre review - Matt Smith and Morfydd Clark hole up in brooding Yorkshire folk-horror
Daniel Kokotajlo's adaptation of Andrew Michael Hurley's novel explores grief and ancient evil through a couple's haunting experience. Set in 1970s Yorkshire, the film delves into dark themes with a s...
By The Guardian | 1 month ago -
Morphic Holding, Boeing rise; Paramount, Devon Energy fall, Monday, 7/8/2024
Stocks on the move: Morphic Holding Inc. (MORF) surged after Eli Lilly's acquisition. Boeing Co. (BA) rose following a guilty plea. Paramount Global (PARA) fell due to a merger. Exxon Mobil Corp....
By AP NEWS | 3 months ago -
Morphic Holding, Inc. (MORF) Stock Price, News, Quote & History - Yahoo Finance
Morphic Holding, Inc. is a biopharmaceutical company focusing on developing integrin therapeutics for various diseases. Their lead product, MORF-057, is in Phase 2 trials for inflammatory bowel diseas...
By Yahoo! Finance | 3 months ago
